# Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

> **NCT06487429** · PHASE2 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 28 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab

## Key facts

- **NCT ID:** NCT06487429
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2026-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487429, "Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06487429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*